We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Raptor Wins FDA Approval For Orphan Drug Procysbi
Raptor Wins FDA Approval For Orphan Drug Procysbi
May 3, 2013
Raptor Pharmaceuticals’ plans for breaking big into biotech took a giant leap forward last week on the FDA’s approval of its lead product Procysbi, an orphan drug targeting some 3,000 patients worldwide who suffer from a rare disease involving cystine buildup in the body.